BR0313150A - Gelatin capsules exhibiting reduced cross-linking - Google Patents

Gelatin capsules exhibiting reduced cross-linking

Info

Publication number
BR0313150A
BR0313150A BR0313150-5A BR0313150A BR0313150A BR 0313150 A BR0313150 A BR 0313150A BR 0313150 A BR0313150 A BR 0313150A BR 0313150 A BR0313150 A BR 0313150A
Authority
BR
Brazil
Prior art keywords
gelatin capsules
linking
reduced cross
exhibiting reduced
capsules exhibiting
Prior art date
Application number
BR0313150-5A
Other languages
Portuguese (pt)
Inventor
Ping Gao
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0313150A publication Critical patent/BR0313150A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)

Abstract

"CáPSULAS DE GELATINA QUE EXIBEM LIGAçãO RETICULADA REDUZIDA". A presente invenção refere-se a composições adequadas para utilização de cápsulas de gelatina, a cápsulas de gelatina apresentando ligação reticulada reduzida e a métodos para preparar essas cápsulas de gelatina."GELATINE CAPSULES DISPLAYING REDUCED RETICULATED CONNECTION". The present invention relates to compositions suitable for use of gelatin capsules, to gelatin capsules having reduced cross-linking and to methods for preparing such gelatin capsules.

BR0313150-5A 2002-07-31 2003-07-31 Gelatin capsules exhibiting reduced cross-linking BR0313150A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39986202P 2002-07-31 2002-07-31
US39977602P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US39986302P 2002-07-31 2002-07-31
PCT/US2003/024045 WO2004010974A2 (en) 2002-07-31 2003-07-31 Gelatin capsule exhibiting reduced cross-linking

Publications (1)

Publication Number Publication Date
BR0313150A true BR0313150A (en) 2005-06-28

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
BR0313149-1A BR0313149A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of stable dissolution profile after storage
BR0313064-9A BR0313064A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound
BR0312875-0A BR0312875A (en) 2002-07-31 2003-07-31 Film-Resistant Gelatin Capsule
BR0313150-5A BR0313150A (en) 2002-07-31 2003-07-31 Gelatin capsules exhibiting reduced cross-linking

Family Applications Before (3)

Application Number Title Priority Date Filing Date
BR0313149-1A BR0313149A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form capable of stable dissolution profile after storage
BR0313064-9A BR0313064A (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound
BR0312875-0A BR0312875A (en) 2002-07-31 2003-07-31 Film-Resistant Gelatin Capsule

Country Status (7)

Country Link
EP (4) EP1526847A2 (en)
JP (4) JP2005538993A (en)
AU (4) AU2003257981A1 (en)
BR (4) BR0313149A (en)
CA (4) CA2493974A1 (en)
MX (4) MXPA05001272A (en)
WO (4) WO2004010974A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524000T3 (en) 2002-06-05 2014-12-03 Teva Czech Industries S.R.O. Reduction of gelatin crosslinking
BRPI0607688A2 (en) 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp method for inhibiting tubulin polymerization in a cell; method for treating or preventing a proliferative disorder in an individual; method of blocking, occluding or otherwise disrupting blood flow to the neovasculature; compound; pharmaceutical composition and use of said method and compound
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
ES2354278T3 (en) * 2005-07-26 2011-03-11 Nicox S.A. PHARMACEUTICAL FORMULATION OF NITROXIDERIVATE OF NSAIDs.
JP5503939B2 (en) * 2009-10-16 2014-05-28 東洋カプセル株式会社 Azelastine hydrochloride-containing capsule
JP6887456B2 (en) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ A film-forming composition containing a surfactant or a surfactant and a salt as a whitening agent.
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
TWI840721B (en) * 2020-12-01 2024-05-01 南韓商Ｌｇ化學股份有限公司 Composite formulation for oral administration comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazol-4-carboxyl acid and a process for the preparation thereof
CN113230241A (en) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 Application of tris (hydroxymethyl) aminomethane salt in medicine for treating cardiovascular and cerebrovascular diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (en) * 1972-11-01 1976-05-14
US4349529A (en) * 1980-04-14 1982-09-14 E. R. Squibb & Sons, Inc. Diagnostic and therapeutic capsules and method of producing
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
FR2617047B1 (en) * 1987-06-23 1991-05-10 Sanofi Sa TANNING RESISTANT GELATIN COMPOSITION, CAPSULES BASED ON THIS COMPOSITION AND THEIR PHARMACEUTICAL APPLICATION, IN PARTICULAR TO FENOFIBRATE
JP2790659B2 (en) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 Gelatin capsule
FI951190A (en) * 1994-03-15 1995-09-16 Senju Pharma Co A method for stabilizing pranoprofen and a stable liquid preparation of pranoprofen
IT1269583B (en) * 1994-04-26 1997-04-08 Bayer Italia Spa PHARMACEUTICAL PREPARATIONS BASED ON A SOLUTION OF KETOPROFENE IN SOFT GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION
DK0695544T3 (en) * 1994-08-05 2001-01-02 Shionogi & Co Hard gelatin capsules that can withstand denaturation and methods of making them
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Also Published As

Publication number Publication date
WO2004010974A3 (en) 2004-08-05
BR0313149A (en) 2005-06-28
WO2004010974A2 (en) 2004-02-05
WO2004010973A2 (en) 2004-02-05
CA2494358A1 (en) 2004-02-05
AU2003257982A1 (en) 2004-02-16
WO2004022032A3 (en) 2004-08-12
AU2003257982A8 (en) 2004-02-16
EP1526845A2 (en) 2005-05-04
EP1526846A2 (en) 2005-05-04
AU2003257102A1 (en) 2004-03-29
AU2003257103A1 (en) 2004-02-16
MXPA05001167A (en) 2005-05-16
AU2003257103A8 (en) 2004-02-16
WO2004010973A3 (en) 2004-08-05
BR0313064A (en) 2005-06-28
WO2004022032A2 (en) 2004-03-18
EP1526844A2 (en) 2005-05-04
JP2006500389A (en) 2006-01-05
AU2003257102A8 (en) 2004-03-29
BR0312875A (en) 2005-06-28
EP1526847A2 (en) 2005-05-04
CA2493980A1 (en) 2004-02-05
CA2493974A1 (en) 2004-03-18
JP2005538994A (en) 2005-12-22
MXPA05000862A (en) 2005-04-19
MXPA05001166A (en) 2005-05-16
AU2003257981A8 (en) 2004-02-16
WO2004010972A2 (en) 2004-02-05
CA2494069A1 (en) 2004-02-05
JP2005538993A (en) 2005-12-22
JP2005538102A (en) 2005-12-15
WO2004010972A3 (en) 2004-07-29
AU2003257981A1 (en) 2004-02-16
MXPA05001272A (en) 2005-04-28

Similar Documents

Publication Publication Date Title
BR0315296A (en) Spirocyclic cyclohexanol derivatives
BRPI0620229A8 (en) formulation
BR0314814A (en) Optimized variants of fc and methods for their generation
BR0307529A (en) N-phenyl-2-pyrimidine amine derivatives
BR0302369A (en) Assembly elements for assembly structures
BR0308339A (en) Indazoles Replaced with Anticancer Activity
GT199900102A (en) PHENOXIPROPANOLAMINES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2184408T3 (en) TRANSDERMAL SYSTEM CONTAINING AN ANTIOXIDANT.
NO20092274L (en) Ansamycin formulations and methods of use thereof
HUP0500084A2 (en) Encapsulation by coating with a mixture of lipids and hydrophobic, high melting point compounds
BR0300709A (en) Perindopril salt and pharmaceutical compositions containing the same
PT1506185E (en) NEW COMPOUNDS AND THEIR UTILIZATION
UY27548A1 (en) SUCCINIC ACID SALTS OF 5,7,14-TRIAZATETRACICLO (10.3.1.02.11.04,9) EXADECA-2 (11), 3,5,7,9-PENTAENO AND PHARMACEUTICAL COMPOSITIONS
BRPI0414809A (en) substituted naphthyl benzothiophene acids
BR0311242A (en) Process for preparing modafinil
PA8575601A1 (en) PROCEDURE FOR PREPARATION, MEDICATIONS THAT INCLUDE THESE COMPOUNDS AND THEIR USE
BRPI0603197A (en) toner composition
BR0313150A (en) Gelatin capsules exhibiting reduced cross-linking
BR0314058A (en) Branched Alcohol Personal Care Compositions
ATE490273T1 (en) GELATIN CAPSULES
BR0213481A (en) Probes
BRPI0408848A (en) oral cladribine formulations
AR002017A1 (en) DERIVATIVES OF FENIL-4-TIAZOLES SUBSTITUTED, PROCEDURE FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND DERIVATIVES DEFENIL-4-TIAZOLES SUBSTITUTED USED IN SUCH PROCEDURE.
BR9812085A (en) "method for the synthesis of quinoline derivatives"
PT1017681E (en) PHARMACEUTICAL AND INTERMEDIATE COMPOUNDS

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A E 7A ANUIDADE(S).

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.